Matthew J. Watt

Matthew J. Watt

Auto-generated profile, based on publicly available information

Matthew J. Watt

Department of Anatomy and Physiology, The University of Melbourne, Melbourne, Victoria, Australia

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2019 in Endocrine Reviews
Verified
Journal Article
Closed access
PDF file
MWMatthew J Watt
Matthew J Watt
PMPaula M Miotto
Paula M Miotto
WNWilliam De Nardo
William De Nardo
MMMagdalene Montgomery
Magdalene Montgomery
The liver is a dynamic organ that plays critical roles in many physiological processes, including the regulation of systemic glucose and lipid metabolism. Dysfunctional hepatic lipid metabolism is a cause of nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disorder worldwide, and is closely associated with insulin resistance and type 2 diabetes. Through the use of advanced mass spectrometry “omics” approaches and detailed experimentation in cells, mice, and humans, we now understand that the liver secretes a wide array of proteins, metabolites, and noncoding RNAs (miRNAs) and that many of these secreted factors exert powerful effects on metabolic processes both in the liver and in peripheral tissues. In this review, we summarize the rapidly evolving field of “hepatokine” biology with a particular focus on delineating previously unappreciated communication between the liver and other tissues in the body. We describe the NAFLD-induced changes in secretion of liver proteins, lipids, other metabolites, and miRNAs, and how these molecules alter metabolism in liver, muscle, adipose tissue, and pancreas to induce insulin resistance. We also synthesize the limited information that indicates that extracellular vesicles, and in particular exosomes, may be an important mechanism for intertissue communication in normal physiology and in promoting metabolic dysregulation in NAFLD.

6 February 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MWMatthew J. Watt
Matthew J. Watt
ACAshlee K. Clark
Ashlee K. Clark
LSLuke Selth
Luke Selth
VHVanessa R. Haynes
Vanessa R. Haynes
NLNatalie Lister
Natalie Lister
RTRenea A. Taylor
Renea A. Taylor
Metabolism alterations are hallmarks of cancer, but the involvement of lipid metabolism in disease progression is unclear. We investigated the role of lipid metabolism in prostate cancer using tissue from patients with prostate cancer and patient-derived xenograft mouse models. We showed that fatty acid uptake was increased in human prostate cancer and that these fatty acids were directed toward biomass production. These changes were mediated, at least partly, by the fatty acid transporter CD36, which was associated with aggressive disease. Deleting Cd36 in the prostate of cancer-susceptible Pten−/− mice reduced fatty acid uptake and the abundance of oncogenic signaling lipids and slowed cancer progression. Moreover, CD36 antibody therapy reduced cancer severity in patient-derived xenografts. We further demonstrated cross-talk between fatty acid uptake and de novo lipogenesis and found that dual targeting of these pathways more potently inhibited proliferation of human cancer-derived organoids compared to the single treatments. These findings identify a critical role for CD36-mediated fatty acid uptake in prostate cancer and suggest that targeting fatty acid uptake might be an effective strategy for treating prostate cancer.

17 January 2013 in Diabetes
Verified
Journal Article
Open access
PDF file
JBJames Boon
James Boon
AHAndrew Hoy
Andrew Hoy
RSRomana Stark
Romana Stark
RBRussell D. Brown
Russell D. Brown
RMRuth C. Meex
Ruth C. Meex
MWMatthew J. Watt
Matthew J. Watt
Dysregulated lipid metabolism and inflammation are linked to the development of insulin resistance in obesity, and the intracellular accumulation of the sphingolipid ceramide has been implicated in these processes. Here, we explored the role of circulating ceramide on the pathogenesis of insulin resistance. Ceramide transported in LDL is elevated in the plasma of obese patients with type 2 diabetes and correlated with insulin resistance but not with the degree of obesity. Treating cultured myotubes with LDL containing ceramide promoted ceramide accrual in cells and was accompanied by reduced insulin-stimulated glucose uptake, Akt phosphorylation, and GLUT4 translocation compared with LDL deficient in ceramide. LDL-ceramide induced a proinflammatory response in cultured macrophages via toll-like receptor–dependent and –independent mechanisms. Finally, infusing LDL-ceramide into lean mice reduced insulin-stimulated glucose uptake, and this was due to impaired insulin action specifically in skeletal muscle. These newly identified roles of LDL-ceramide suggest that strategies aimed at reducing hepatic ceramide production or reducing ceramide packaging into lipoproteins may improve skeletal muscle insulin action.

1 March 2025 in Journal of Hepatology
Verified
Journal Article
Open access
GSGregory R. Steinberg
Gregory R. Steinberg
CVCelina M. Valvano
Celina M. Valvano
WNWilliam De Nardo
William De Nardo
MWMatthew J. Watt
Matthew J. Watt
The liver acts as a central metabolic hub, integrating signals from the gastrointestinal tract and adipose tissue to regulate carbohydrate, lipid, and amino acid metabolism. Gut-derived metabolites, such as acetate and ethanol, and non-esterified fatty acids from white adipose tissue influence hepatic processes, which rely on mitochondrial function to maintain systemic energy balance. Metabolic dysregulation caused by obesity, insulin resistance, and type 2 diabetes disrupts these pathways, leading to metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH). In this review, we explore the metabolic fluxes within the gut-adipose tissue-liver axis, focusing on the pivotal role of de novo lipogenesis, dietary substrates like glucose and fructose, and changes in mitochondrial function during MASLD progression. We also highlight the contributions of white adipose tissue insulin resistance and impaired mitochondrial dynamics to hepatic lipid accumulation. Further understanding how the interplay between substrate flux from the gastro-intestinal tract integrates with adipose tissue and intersects with structural and functional alterations to liver mitochondria will be important to identify novel therapeutic targets and advance the treatment of MASLD and MASH.

1 December 2015 in Cell Metabolism
Verified
Journal Article
Closed access
RMRuth C. Meex
Ruth C. Meex
AHAndrew Hoy
Andrew Hoy
AMAlexander Morris
Alexander Morris
RBRussell D. Brown
Russell D. Brown
JLJennifer C.Y. Lo
Jennifer C.Y. Lo
MWMatthew J. Watt
Matthew J. Watt

1 April 2019 in Cell Reports
Verified
Journal Article
Open access
ARArthe Raajendiran
Arthe Raajendiran
GOGeraldine Ooi
Geraldine Ooi
JBJackie Bayliss
Jackie Bayliss
POPaul E. O’bRien
Paul E. O’bRien
Ralf B. SchittenhelmRalf B. Schittenhelm
Ralf B. Schittenhelm
MWMatthew J. Watt
Matthew J. Watt
Adipocyte progenitor cells (APCs) provide the reservoir of regenerative cells to produce new adipocytes, although their identity in humans remains elusive. Using FACS analysis, gene expression profiling, and metabolic and proteomic analyses, we identified three APC subtypes in human white adipose tissues. The APC subtypes are molecularly distinct but possess similar proliferative and adipogenic capacities. Adipocytes derived from APCs with high CD34 expression exhibit exceedingly high rates of lipid flux compared with APCs with low or no CD34 expression, while adipocytes produced from CD34- APCs display beige-like adipocyte properties and a unique endocrine profile. APCs were more abundant in gluteofemoral compared with abdominal subcutaneous and omental adipose tissues, and the distribution of APC subtypes varies between depots and in patients with type 2 diabetes. These findings provide a mechanistic explanation for the heterogeneity of human white adipose tissue and a potential basis for dysregulated adipocyte function in type 2 diabetes.